AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,376.50GBp
9:31am EDT
Change (% chg)

34.50p (+0.80%)
Prev Close
4,342.00p
Open
4,352.00p
Day's High
4,382.00p
Day's Low
4,320.50p
Volume
1,236,033
Avg. Vol
2,465,324
52-wk High
4,931.68p
52-wk Low
4,019.00p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company's medicines include Crestor for... (more)

Overall

Beta: 0.56
Market Cap(Mil.): £55,002.06
Shares Outstanding(Mil.): 1,263.67
Dividend: 57.50
Yield (%): 4.20

Financials

  AZN.L Industry Sector
P/E (TTM): 72.75 37.25 40.68
EPS (TTM): 0.60 -- --
ROI: 2.91 16.52 15.78
ROE: 5.85 17.30 16.82
Search Stocks

BRIEF-AstraZeneca, Isis Pharmaceuticals announce strategic collaboration

* AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases

03 Aug 2015

Express Scripts excludes 20 more drugs from 2016 coverage

NEW YORK, July 31 - Express Scripts Holding Corp , the largest U.S. pharmacy benefit manager, said on Friday that it would exclude about 20 new medications in 2016 from insurance coverage, including two diabetes drugs and a weight loss drug.

31 Jul 2015

AstraZeneca beats profit forecasts, helped by external deals

LONDON - AstraZeneca revenue fell by a smaller-than-expected 7 percent in the second quarter, as income from selling rights to medicines offset generic competition to older drugs and a strong dollar. | Video

30 Jul 2015

BRIEF-AstraZeneca CEO says absolutely on track to meet mid and long-term targets

July 30 - AstraZeneca CEO Pascal Soriot told reporters: * CEO says absolutely on track to meet mid and long-term targets * CEO says externalisation deal-making will continue in H2 * CFO says externalisation deal-making revenues will be lower in H2 * For more news, please click here

30 Jul 2015

UPDATE 2-AstraZeneca beats profit forecasts, helped by external deals

* Q2 externalisation income $471 million (Adds details on drugs, latest shares)

30 Jul 2015

AstraZeneca beats profit forecasts, helped by external deals

LONDON, July 30 - AstraZeneca revenue fell by a smaller-than-expected 7 percent in the second quarter, as income from spinning off assets offset generic competition to older medicines and a strong dollar.

30 Jul 2015

AstraZeneca sells rare cancer drug to Sanofi for up to $300 million

LONDON - AstraZeneca , under pressure from falling sales of older drugs, is selling a medicine for a rare type of cancer to Sanofi as it continues a drive to raise cash by divesting certain assets.

27 Jul 2015

UPDATE 1-AstraZeneca sells rare cancer drug to Sanofi for up to $300 mln

LONDON, July 27 - AstraZeneca, under pressure from falling sales of older drugs, is selling a medicine for a rare type of cancer to Sanofi as it continues a drive to raise cash by divesting certain assets.

27 Jul 2015

European Factors-Futures lower as China woes spread

LONDON, July 27 - European equities were seen starting the week on a downbeat note, with futures trading lower after lingering fears over China's economic growth prospects and a sharp commodities sell-off rippling through global markets.

27 Jul 2015

AstraZeneca sells rare cancer drug to Sanofi for up $300 mln

LONDON, July 27 - AstraZeneca, under pressure from falling sales of older drugs, is selling a medicine for a rare type of cancer to Sanofi as it continues a drive to raise cash by divesting certain assets.

27 Jul 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$49.00
Provider : ValuEngine, Inc.
$25.00
Provider : GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks